WuXi AppTec (OTCMKTS:WUXAY – Get Free Report) was upgraded by equities research analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research report issued on Tuesday, Zacks reports.
WuXi AppTec Stock Up 12.7%
OTCMKTS:WUXAY opened at $25.11 on Tuesday. WuXi AppTec has a 52 week low of $12.45 and a 52 week high of $28.69. The firm’s 50-day simple moving average is $25.41 and its 200 day simple moving average is $19.36.
WuXi AppTec Company Profile
WuXi AppTec is a global pharmaceutical and biotechnology services company that provides contract research, development and manufacturing services. The company supports drug developers throughout the product life cycle, from early-stage discovery and laboratory testing through clinical development and commercial production.
Its offerings include medicinal and synthetic chemistry, biology research, preclinical and clinical testing, regulatory support, pharmaceutical manufacturing, and the development and manufacturing of advanced therapies.
Featured Articles
- Five stocks we like better than WuXi AppTec
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for WuXi AppTec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WuXi AppTec and related companies with MarketBeat.com's FREE daily email newsletter.
